Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH

Currently, five classes of drug are approved for the treatment of pulmonary arterial hypertension (PAH): phosphodiesterase 5 inhibitors (PDE5i); endothelin receptor antagonists; prostacyclin analogs; the IP receptor agonist selexipag; and the soluble guanylate cyclase (sGC) stimulator riociguat. For...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pulm Circ
Autors principals: Benza, Raymond L., Corris, Paul A., Ghofrani, Hossein-Ardeschir, Kanwar, Manreet, McLaughlin, Vallerie V., Raina, Amresh, Simonneau, Gérald
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2020
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7074518/
https://ncbi.nlm.nih.gov/pubmed/30803329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045894019837849
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars